-
Blood: Breaking the MALT1 feedback mechanism may maximize the anti-lymphoma efficacy of MALT1 inhibitors.
Time of Update: 2020-09-22
In these cell line, inhibition of MALT1 promotes an increase in mTORC1 activity and phosphorylation levels in S6K1-T389 and S6-S235/6, which is only partially blocked by PI3Kd inhibition inside and outside the body.
-
Blood: Single-cell DNA amplification sequencing reveals the cloning heterogeneity and evolution of T-ALL.
Time of Update: 2020-09-22
In order to gain more understanding of cloning heterogeneity levels during diagnosis and treatment, Servera and others used Tapestri platforms to sequence single-cell targeted DNA, design a custom ALL panel, and obtain accurate single nucleotide mutations and small fragments of insertion-missing mutations, requiring each sample to measure about 4,400 cells at a time, covering 110 genes.
-
Inventory: A selection of Blod research on September 3, 2020.
Time of Update: 2020-09-22
BTKi treatment CLL at the time of diagnosis of COVID-19 does not affect the survival of the patient (CFR: 34% vs 35%).
-
The FDA has granted Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of chronic lymphocytic leukemia.
Time of Update: 2020-09-22
Biotech company Aachen Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has awarded the new Bcl-2 inhibitor APG-2575 orphan drug title (ODD) for the treatment of chronic lymphocytic leukemia (CLL).
APG-2575 is a new oral Bcl-2 selective inhibitor developed by Asaan Pharmaceuticals.
-
Lancet Haematol: Venetoclax combined with Siddarabin 10-day therapy to treat the efficacy of various AML subsypes.
Time of Update: 2020-09-22
the medium overall survival of newly diagnosed AML, untreated secondary AML, treated secondary AML and recurring/resusable AML patients was 18.1 months (95% CI 10.0-not achieved), 7.8 months (2.9-10.7), 6.0 months (3).
-
The body has blood clots, 5 places will reveal the "break"! I can't hide it at all.
Time of Update: 2020-09-22
Second, blood clots are most likely to "tie" five categories of people sitting for a long time, will lead to blood flow, increase the risk of thrombosis, such as office workers, drivers, pilots and so on.
-
EBMT 2020: LNP023 achieved positive results in the treatment of hairy nocturnal hemoglobinuria (PNH).
Time of Update: 2020-09-22
S. Professor Peffault de Latour, of the University of Paris, said: "These new data clearly show that LNP023 can control the hemolysis mechanism of the disease and may change the way PNH is treated." .
-
Blood: Venetok Unilitoximassi-benzomostin is used to treat recurring/refractic follicle lymphoma.
Time of Update: 2020-09-22
The CONTRALTO trial is an open-label Phase 2 study designed to evaluate the efficacy and safety of BCL-2 inhibitor Venetok (VEN) Vitoxy monoantigen (R), VEN combined benzodiamostin (B) and R, compared to BR alone to treat recurring/refractic follicle lymphoma.
-
Blood: Effect of telomere length on prognosis in patients with hematopoietic stem cell transplantation.
Time of Update: 2020-09-22
Allogeneic hematopoietic stem cell transplantation is the only potential cure for patients with marrow growth syndrome (MDS), but long-term survival is limited by the risk of transplant-related complications.
-
FDA approves Onureg (azacitidine) treatment for acute myeloid leukemia (AML)
Time of Update: 2020-09-22
Recently, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's Onureg (azacitidine) for the treatment of acute myeloid leukemia (AML) in adults: CR patients who have been fully remissiond for the first time after intensive induction chemotherapy (CR) or who have not completed the recovery of blood cell counts can continue to use azacline therapy.
-
Blood:c-Myc hemomethic dose is insufficient in the role of HSC maintenance.
Time of Update: 2020-09-22
first time, researchers have found that insufficient doses of Apc monohyma can induce red line differentiation block by promoting bone marrow endothort cell expression and secretion of IL-6.
-
Future Science Awards announced, Zhang Tingdong / Wang Zhenyi won the Life Sciences Award!
Time of Update: 2020-09-22
Future Science Award Winners Previous Life Sciences Award Winners Introduced the First Winners - Lu Yuming recognizes his pioneering contribution to non-invasive prenatal fetal genetic testing based on the discovery of fetal DNA in the extraterrestal blood of pregnant women.
-
Blood: The beta-catenin-TCF/LEF signal promotes granulocyte differentiation by raising the G-CSF subject.
Time of Update: 2020-09-22
Central point: beta-catenin-TCF/LEF interaction barriers can disrupt steady-state and emergency particle production, and TCF/LEF factors regulate G-CSF subject expression by interacting directly with Csf3r's initiators and enhancer regions.
-
FDA approved CD38 monoantigendarZALEX (daratumumab) in a joint with kafezome and dexamisson to treat recurring or refractic multiple myeloma.
Time of Update: 2020-09-22
Danish biopharmaceutical company Genmab has announced that the U.S. Food and Drug Administration (FDA) has approved its CD38 monoantigenist DARZALEX (daratumumab) in a joint treatment with Kafezome and Desemisson (DKD) to treat adult patients with relapsed/refractic multiple myeloma after 1-3 treatments.
-
Blood: Detection of glycolysis metabolism of pathogenic T cells with 13C-MRI or early detection of GvHD.
Time of Update: 2020-09-22
Given that increased glycolysis is an early feature of T-cell activation, Assmann and others speculate that in vivo glycolysis metabolic imaging can detect liver GvHD invasively, as GvHD occurs when activated CD4-T cells enter.
-
Blood: The role of fusion transcription factor PML/RAR alpha in the progression of acute early granulocytic leukemia.
Time of Update: 2020-09-22
Central point: The direct target map of ML/RAR alpha redefines activation through super-enhancers and explains the synergy of ATRA/ATO; : Transcription disorders caused by carcinogenic fusion proteins play a vital role in leukemia.
-
Blood: The Otub1/c-Maf axis may be a potential therapeutic target for multiple myeloma.
Time of Update: 2020-09-22
the study, the researchers found that the Otub1/c-Maf axis could be a potential target.
Otub1 can abolish polypronination of c-Maf K48 connections, preventing degradation and enhancing their transcriptional activity.
, the Otub1/c-Maf axis may be a therapeutic target for MM.
-
Is a blood transfusion a full blood transfusion? You may need to enter plasma!
Time of Update: 2020-09-02
(9) acute haemorrhagic infusion of a large number of relatively long-term red blood cell preparations, still bleeding more than, need to be infused with fresh frozen plasma.
(11) to fight a drug overdose and need to infus fresh frozen plasma.
-
Blood: High plasma GDF-15 levels are associated with an increased risk of venous thrombosis.
Time of Update: 2020-09-02
results, the OR value of VTE increases in the GDF-15 quarter digits (trend P.002).
results of this study show that high GDF-15 levels are associated with increased risk of VTE, but Mendel's random analysis suggests that this link is not causal.
-
Blood: New sub-type - tissue resident memory B cells.
Time of Update: 2020-09-01
Although human B cells have been widely studied, most of the reports have been carried out using outer blood as the source of B cells.
, the study provides new insights into the functional characteristics of human B-cell chambers in multiple tissues.
